BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 9, 2007, Pages 1361-1367

  Hay, Robert ^a   MacRae, Erin ^a   Barber, Duane ^a   Khalil, Moosa ^a   Demetrick, Douglas J ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b HMRB   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PARAFFIN; DNA;

ADULT; AMINO ACID SEQUENCE; ARTICLE; ASPIRATION BIOPSY; CANCER INVASION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA SEQUENCE; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC CODE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; JUVENILE MELANOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MELANOMA; MELTING POINT; POLYMERASE CHAIN REACTION; PROTO ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; THYROID PAPILLARY CARCINOMA; V600K ONCOGENE; VK600 1E GENE; GENETICS; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; MUTATION; NEEDLE BIOPSY; NUCLEOTIDE SEQUENCE; PAPILLARY CARCINOMA; PATHOLOGY; PIGMENTED NEVUS; SKIN TUMOR; THYROID TUMOR;

BASE SEQUENCE; BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; DNA, NEOPLASM; HUMANS; MELANOMA; MOLECULAR SEQUENCE DATA; MUTATION; NEVUS, PIGMENTED; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; THYROID NEOPLASMS;

EID: 34548775938     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp UR. The ins and outs of Raf kinases. Trends Biochem Sci. 1994;19:474-480.
2. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93:53-62.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
4. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta. 2005;1756:81-82.
5. Basto D, Trovisco V, Lopes JM, et al. Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol (Berl). 2005;109:207-210.
6. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62:6997-7000.
7. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625-627.
8. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22:6455-6457.
9. Loewe R, Kittler H, Fischer G, et al. BRAF kinase gene V599E mutation in growing melanocytic lesions. J Invest Dermatol. 2004;123:733-736.
10. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 2002;62:7001-7003.
11. Xing M, Vasko V, Tallini G, et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab. 2004;89:1365-1368.
12. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855-867.
13. Thomas NE. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res. 2006;16:97-103.
14. Jin L, Sebo TJ, Nakamura N, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol. 2006;15:136-143.
15. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19-20.
16. Uribe P, Wistuba I, Gonzalez S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol. 2003;25:365-370.
17. Gill M, Renwick N, Silvers DN, Celebi JT. Lack of BRAF mutations in Spitz nevi. J Invest Dermatol. 2004;122:1325-1326.
18. Barnhill RL, Flotte TJ, Fleischli M, Perez-Atayde A. Cutaneous melanoma and atypical Spitz tumors in childhood. Cancer. 1995;76:1833-1845.
19. Mihic-Probst D, Perren A, Schmid S, et al. Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma. Anticancer Res. 2004;24:2415-2418.
20. Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol. 2003;121:1160-1162.
21. La Porta C, Cardano R, Facchetti F, et al. BRAF V599E mutation occurs in Spitz and Reed naevi. J Eur Acad Dermatol Venereol. 2006;20:1164-1165.
22. Fullen DR, Poynter JN, Lowe L, et al. BRAF and NRAS mutations in spitzoid melanocytic lesions. Mod Pathol. 2006;19:1324-1332.
23. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457.
24. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22:4578-4580.
25. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch. 2004;444:572-576.
26. Di Cristofaro J, Marcy M, Vasko V, et al. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum Pathol. 2006;37:824-830.
27. Lee JH, Lee ES, Kim YS, Won NH, Chae YS. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology. 2006;38:201-204.
28. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol. 2004;202:247-251.
29. Sapio MR, Posca D, Troncone G, et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol. 2006;154:341-348.
30. Ciampi R, Zhu Z, Nikiforov YE. BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr Pathol. 2005;16:99-105.
31. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30:216-222.
32. Hu S, Liu D, Tufano RP, et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer. 2006;119:2322-2329.
33. Tyler DS, Shaha AR, Udelsman RA, et al. Thyroid cancer: 1999 update, Ann Surg Oncol. 2000;7:376-398.
34. Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab. 2004;89:2867-2872.
35. Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:5175-5180.
36. Cohen Y, Rosenbaum E, Clark DP, et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res. 2004;10:2761-2765.
37. Mojica WD, Khoury T. Presence of the BRAF V600E point mutation in morphologically benign appearing thyroid inclusions of cervical lymph nodes. Endocr Pathol. 2006;17:183-189.
38. Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology. 2007;148:936-941.
39. Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum Pathol. 2005;36:486-493.
40. Turner DJ, Zirvi MA, Barany F, Elenitsas R, Seykora J. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction. J Cutan Pathol. 2005;32:334-339.
41. Puxeddu E, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab. 2004;89:2414-2420.
42. Ikenoue T, Hikiba Y, Kanai F, et al. Rapid detection of mutations in the BRAF gene using real-time polymerase chain reaction and melting curve analysis. Cancer Genet Cytogenet. 2004;149:68-71.
43. Oler G, Ebina KN, Michaluart P Jr, Kimura ET, Cerutti J. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol (Oxf). 2005;62:509-511.
44. Horton RM, Ho SN, Pullen JK, et al. Gene splicing by overlap extension. Methods Enzymol. 1993;217:270-279.
45. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene. 1989;77:61-68.
46. Karasarides M, Chiloeches A, Hayward R, et al. B-RAF is a therapeutic target in melanoma. Oncogene. 2004;23:6292-6298.
47. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95:1878-1890.
48. Edwards RH, Ward MR, Wu H, et al. Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet. 2004;41:270-272.
49. Trovisco V, Soares P, Soares R, et al. A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol. 2005;36:694-697.
50. Rowe LRM, Bentz BGM, Bentz JSM. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal. 2006;3:10.